$PFE

Generating a unique summary for PFE…

AI-generated for information only — not investment advice.

Global pharma and vaccines.

Institutions hold —% · insiders —%

No institutional filings available for this ticker.

No insider transactions reported.

Consensus score — (1 = strong buy, 5 = sell) · mean target —

No recent analyst actions.

Next report: not scheduled

No earnings history available.

No filings indexed for this ticker.

• Forget the Dividend. This Could Be the Real Reason to Buy Pfizer Stock Now

  Pfizer's 5.91% yield draws most of the headlines, but a quietly rerated stock and a pipeline loaded with 2026 catalysts are building a separate case altogether for investors willing to look past the dividend.

  Mon, 07 Sep 2026 17:00:45 +0000

• This Is What I'd Do With Pfizer Stock Right Now

  The pharmaceutical stock is struggling, but its dividend can be highly valuable to income investors.

  Mon, 07 Sep 2026 15:50:01 +0000

• Vaccines Global Market Intelligence Report 2026-2035 Featuring Bio Farma, Emergent BioSolutions, GC Pharma, GlaxoSmithKline, Janssen, Merck, Novavax, Moderna, Pfizer, Sanofi Pasteur, and Valneva

  Dublin, Sept. 07, 2026 (GLOBE NEWSWIRE) -- The "Vaccines Market Distribution by Type of Vaccine API, Targeted Patient Population, Type of Vaccines, Route of Administration, and Key Geographical Region - Trends and Forecasts Till 2035" has been added to ResearchAndMarkets.com's offering. The global vaccines market is projected to increase from approximately USD 48 billion to USD 94 billion by 2030, representing a compound annual growth rate of about 11.9% during the forecast period. Market expans

  Mon, 07 Sep 2026 11:02:00 +0000

• AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026?

  AbbVie's immunology pivot is offsetting Humira's decline, while Pfizer trades at half the valuation despite patent risks ahead.

  Fri, 04 Sep 2026 18:50:01 +0000

• Pfizer’s Stock Has Been Crushed—Is Its 6% Dividend Finally Worth Buying?

  Pfizer shareholders are collecting a 6% yield while the stock bleeds value, and the CEO just made a bold promise about keeping that payout alive through what could be the company's toughest stretch in years.

  Fri, 04 Sep 2026 13:42:11 +0000

• Ionis’ rare neurology drug approved; Pfizer inks an ADC deal

  Zanvastro is now the first approved medicine for Alexander disease. Elsewhere, an immune system specialist posted positive results and a cell therapy developer turned to layoffs.

  Fri, 04 Sep 2026 09:00:00 +0000

• Pfizer (PFE) Stock Looks Fully Valued As Earnings Run Ahead Of Value

  Pfizer stock has quietly put up a 25.6% gain over the past year, yet broad valuation checks still do not flag it as either clearly cheap or clearly expensive. With mixed signals on value and fresh product news in the background, investors are weighing how much of the recent optimism is already reflected in the share price. The 25.6% 1 year return suggests sentiment toward Pfizer has improved meaningfully, which raises the bar for further upside driven purely by valuation. Approval of Pfizer...

  Fri, 04 Sep 2026 01:07:38 +0000

• Pfizer (PFE) After FDA Vaccine Approval Faces A Fair Value Reality Check

  Pfizer (PFE) has drawn fresh attention after the FDA approved its 2026 to 2027 COMIRNATY XFG COVID-19 vaccine formula for high risk age groups, adding a new chapter to the company’s vaccine story. Pfizer’s recent FDA approval adds to a string of positive updates that helped lift the share price to around a two year high, with a 30 day share price return of 13.38% and year to date share price return of 14.42%. The 1 year total shareholder return of 25.63% contrasts with a weaker 5 year total...

  Fri, 04 Sep 2026 00:22:05 +0000